- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zevra Therapeutics Inc (ZVRA)
Track today's live Zevra Therapeutics (ZVRA) share price, performance and key data on this page with our current NASDAQ:ZVRA stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Zevra Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ZVRA share price, head to our technical summary section, which provides analysis on Zevra Therapeutics share price buy/sell indicators using real-time data (or discuss the Zevra Therapeutics (ZVRA) stock price today with other investors in the Zevra Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ZVRA share price (ISIN: US4884452065) to enhance your trading decisions with our free investment tools and resources.
What Is the Zevra Therapeutics Inc Share Price Today?
The Zevra Therapeutics share price today is 11.160.
What Is the Stock Symbol for Zevra Therapeutics Inc
The stock symbol (or 'ticker') for Zevra Therapeutics Inc is "ZVRA."
What Stock Exchange Does Zevra Therapeutics Inc Trade On?
Zevra Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Zevra Therapeutics Inc a Good Stock to Buy?
Determining whether Zevra Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ZVRA share price (ISIN: US4884452065) to enhance your trading decisions with our free investment tools and resources.
What Is the Zevra Therapeutics Inc Share Price Today?
The Zevra Therapeutics share price today is 11.160.
What Is the Stock Symbol for Zevra Therapeutics Inc
The stock symbol (or 'ticker') for Zevra Therapeutics Inc is "ZVRA."
What Stock Exchange Does Zevra Therapeutics Inc Trade On?
Zevra Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Zevra Therapeutics Inc a Good Stock to Buy?
Determining whether Zevra Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.150
11.770
52 wk Range
8.010
15.035
ZVRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.15011.770
52 wk Range
8.01015.035
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZVRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
25.250
Upside
+126.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 8K Zevra Therapeutics Inc For: 3 November
- Investing.com
- Form 8K Zevra Therapeutics Inc For: 3 November
- Investing.com
- Form 144 Zevra Therapeutics For: 17 October
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.250
(+126.25% Upside)
Zevra Therapeutics Inc SWOT Analysis
MIPLYFFA's Triumph | Zevra's flagship drug exceeds expectations with $17.1M Q1 sales, driving analyst projections to $80M for 2025 and $117M for 2026 |
Financial Fortitude | Explore Zevra's robust $217M cash position, extending runway to 2029 and fueling strategic growth initiatives in the rare disease market |
Pipeline Potential | Delve into Zevra's diverse portfolio, including OLPRUVA's growth strategies and the promising Phase 3 trial of celiprolol for VEDS |
Global Ambitions | Learn about Zevra's European expansion plans for MIPLYFFA, with regulatory submission slated for late 2025 and encouraging data from French EAP |
Zevra Therapeutics Inc Earnings Call Summary for Q3/2026
- Zevra Q3 2026 EPS of $0.26 beat estimates by 62.5%; revenue rose 45% YoY to $37.8M, driven by MIPLYFFA's $34M in U.S. sales.
- Net income swung to $19.2M from $0.5M loss a year ago; gross margin hit 95.5% as rare-disease therapy MIPLYFFA scaled profitably.
- Company plans Q1 2027 sNDA filing to expand MIPLYFFA label to infants under 24 months; CHMP opinion on European approval expected Q4 2026.
- Management sees larger-than-expected patient pool for Niemann-Pick disease; disease awareness site visits surged 123% quarter-over-quarter.
- Shares rose 2.34% after-hours to $10.50; analysts set price targets of $20-$35, citing strong fundamentals and undervaluation at 10.7x P/E.
Last Updated: 03/11/2026, 22:22
Read Full TranscriptEarnings
Latest Release
03/11/2026
EPS / Forecast
0.26 / 0.16
Revenue / Forecast
37.8M / 37.08M
Compare ZVRA to Peers and Sector
Metrics to compare | ZVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZVRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.9x | 4.9x | −0.2x | |
PEG Ratio | 0.07 | −0.18 | 0.00 | |
Price/Book | 2.8x | 1.0x | 2.6x | |
Price / LTM Sales | 4.5x | 1.7x | 2.8x | |
Upside (Analyst Target) | 126.3% | 114.5% | 63.4% | |
Fair Value Upside | Unlock | 0.7% | 9.5% | Unlock |
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Zevra Therapeutics (NASDAQ: ZVRA) Share Price Today?
The Zevra Therapeutics stock price today is 11.160 USD.
What Stock Exchange Does Zevra Therapeutics (ZVRA) Trade On?
Zevra Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Zevra Therapeutics?
The stock symbol (also called a 'ticker') for Zevra Therapeutics is "ZVRA."
What Is the Current Zevra Therapeutics Market Capitalisation?
As of today, Zevra Therapeutics (NASDAQ: ZVRA) market cap is 664.070M USD.
What Is Zevra Therapeutics's (ZVRA) Earnings Per Share (TTM)?
The Zevra Therapeutics EPS is currently 1.29 (Trailing Twelve Months).
When Is the Next Zevra Therapeutics Earnings Date?
Zevra Therapeutics's next earnings report will be released on 10/03/2027.
Is ZVRA a Buy or Sell From a Technical Analyst Perspective?
Based on today's Zevra Therapeutics moving averages and other technical indicators, the daily buy/sell signal for ZVRA stock is Strong Buy.
How Many Times Has Zevra Therapeutics Stock Split?
Zevra Therapeutics has split 1 times. (See the ZVRA stock split history page for full effective split date and price information.)
How Many Employees Does Zevra Therapeutics Have?
Zevra Therapeutics has 61 employees, based on their latest Companies House report.
What is the current trading status of Zevra Therapeutics (NASDAQ: ZVRA)?
As of 13/11/2026, Zevra Therapeutics (ZVRA) is trading at a share price of 11.160 USD, with a previous close of 11.160 USD. The stock has fluctuated within a day range of 11.150 USD to 11.770 USD, while its 52-week range spans from 8.010 USD to 15.035 USD.
What Is Zevra Therapeutics (ZVRA) Price Target According to Analysts?
The average 12-month price target for Zevra Therapeutics is 25.250 USD, with a high estimate of 35 USD and a low estimate of 20 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +126.25% Upside potential.
What Is the ZVRA Premarket Price?
ZVRA's last pre-market stock price is 11.690 USD. The pre-market share volume is 650.000, and the stock has decreased by -0.160, or -1.350%.
What Is the ZVRA After Hours Price?
ZVRA's last after hours stock price is 10.820 USD, the stock has decreased by -0.340, or -3.050%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.